12 May 2004 | News
views
Future prospects of biotechnology in India
"There
are several segments, which have good prospects for the growth of biotechnology
in the country. Health and agriculture are two promising areas. In the last two
to three years, we have had good signs of growth in these segments. But the next
five years will be crucial for the biotech industry. There are some societal
aspects that require proper attention. Areas like vaccines, bio therapeutics and
diagnosis hold good potential for the development of the entire biotech
industry. There are some areas that are yet to be explored even though we have
expertise in those areas. Among these, immunotherapeutics offers a great
opportunity for development. We, as a nation, need to focus on this area and
come up with something good."
Dr MK Bhan
Secretary, Department of Biotechnology
On the need of a clinical data management course
"India
can become a major hub for clinical trials in the world. We have enough
biodiversity available here. We have a very good hospital system. Many hospitals
are interested to have a tie up with research organizations of the western world
and many people are exposed to newer drugs and they want to do the clinical
trials. What we require is a proper channel for collecting the data, organizing
and analyzing the same. The problem we are facing is collection of data and how
to organize it. Today if we see, clinical data management is not included in any
syllabus. It needs to be put in an organized way."
Prof. AS Kolaskar,
Vice Chancellor, University of Pune
On biotech education in India
"These
were some government initiatives, which have served the country very well. But
now the tendency is a mushrooming of biotechnology courses in the country
without proper quality and infrastructure, because the name biotechnology sells.
This is something that has to be attended to. I think that we do not have
quality control on many of the courses started by the university unlike the DBT
courses. Indian scientists and researchers are a very large reservoir of trained
manpower but in the name crass commercialization we are systematically
destroying the system that has helped them evolve. This is a matter of grave
concern."
Prof. M Vijayan,
Associate Director, IISc, Bangalore
Potential of biotech industry
"The
beauty of the biotechnology industry is that it has multifaceted requirement
unlike software industry, which needs only homogenous skill. A company like ours
has biologists, chemists, genetic scientists, microbiologists, mechanical,
chemical, electrical engineers, regulatory people, doctors, lawyers and so on.
This shows the huge potential of the industry in generating various kinds of
jobs."
Ms Kiran Mazumdar-Shaw
Chairman and Managing Director, Biocon
Human resource development in food biotech
"CFRTI
offers a masters course (MSc) in food technology, which teaches a lot of
biotechnology. The course incorporates investigational problems, which are
biotech oriented. This degree program gives a tremendous amount of input to the
students so that they go back to industry, work there and introduce the concept
of biotechnology. The institute also has PhD students working in the different
departments and about 1/3 of them (100 plus) are working on biotechnology in
one-way or the other. We also have short-term courses, where we have the
industries and entrepreneurs coming in. But, I would like to emphasize on their
quality. Quality is nothing but knowledge and skill combined with the art of
doing things with innovation. The quality of education at CFTRI should be a good
benchmark for others to follow. Our food technology graduates are # 1in the
country, and perhaps in the SouthEast Asia region also."
Dr V Prakash
Director, CFTRI, Mysore
Government research institutes vs the private sector?
"Government
institutes and the Indian private sector establishments span a wide range in
terms of facilities. But the best government organizations offer facilities
superior to the best private sector establishments at present. Moreover,
government organizations like CSIR have a large network, which enables optimal
utilization of pooled resources. Growth prospects have traditionally been better
in private organizations but with the increasing trend to break out of time
bound promotion patterns; the trend is likely to change. Salaries are relatively
lower in government organizations but the freedom and creativity nurtured,
factors, which are very critical in research, by the environment in a young and
growing research institute like IGIB still attracts the best talent."
Dr SK Brahmachari,
Director Institute of Genomics and Integrative Biology (IGIB), New Delhi
About current generation biotech researchers
"Though
there is a general feeling that Indian science is going down but in modern
biology and biotechnology first class research is going on in India. Researchers
are publishing papers in high impact international journals. Thanks to
government support especially the Department of Biotechnology that has promoted
research by establishing centers, infrastructure and national facilities all
over India. This is showing up today. Excellent science is going on."
Prof G Padmanabhan
Distinguished biotechnologist, Honorary professor, Indian
Institute of Science, Bangalore
Synergy between government research institutes and the private sector
"The
concept of R&D based pharma sector is fast picking up and private sector has
invested in basic research for the discovery and development of new drugs.
However, only a few disease areas are covered by these pharma companies as their
selection is directed solely by the market size and business opportunities. The
priorities of government institutions especially a drug research laboratory are
driven more by societal welfare and knowledge contribution. Such institutions
are therefore not only centers of excellence but also provide centralized
infrastructure to cater to the practical skill development of students and
mid-career professionals."
Dr CM Gupta
Director Central Drug research Institute (CDRI), Lucknow
Future of BioPharma
"A
biotech drug has no chemical substitute. Biotechnological drugs are in a much
better position to establish the kind of therapeutics that are required. There
is no treatment in those areas. When I started it appeared to me that in 10-15
years it is going to become more and more important. That is what is happening
now."
Habil Khorakiwala
Chairman and Managing Director, Wockhardt Ltd
Opportunities in the clinical trials area
"The
job categories could be multifaceted like coordinator, monitor, research
associate, clinical research physician, trial materials manager, project
manager, medical writers, data managers, data entry persons, lab technicians
etc. The field requires postgraduates in the relevant field with a scientific
background and bent of mind for clinical trials."
Rajiv Gulati
Managing director and chairman, Eli Lilly and Company (India)
Pvt Ltd, Gurgoan
On human resource
"The
biotech industry is a highly knowledge-intensive one and human resource is its
prime asset and strength. Quite like the IT sector was in the early 90's, the
biotech sector too is witnessing a lot of hype leading to expectations and is
definitely a sunrise sector for any job-seeker. Hence, there is demand for
qualified and experienced personnel. For the R&D job seeker, what is needed
is the right exposure to the scientific way of working and the mindset to
experiment and innovate. And patience to see R&D translate into commercial
success."
Varaprasad Reddy
Managing Director, Shantha Biotech, Hyderabad
New entrants in this field should have…
"We
look for scientific performance, novel ideas, integrity, ability to provide
leadership, ability to work in a team, desire to achieve goals in shortest-time
possible and desire to apply the scientific knowledge into human cause."
Dr Lalji Singh
Director Center for Cellular and Molecular Biology (CCMB),
Hyderabad
Fusion of ancient wisdom and modern sciences
"India
can develop world-class products by fusing ancient wisdom and modern sciences
because new products cannot compete with products, which have only tradition and
empirical observation as the knowledge base. The knowledge to be integrated into
the traditional products has to emerge from modern science, especially modern
biology and chemistry. Such fusion will lead to better definition of existing
products, improved understanding of the mechanism of their action, modified
composition at molecular level and better understanding of interactions amongst
various molecules."
Dr RA Mashelkar
Director General, CSIR